1. Microparticle encapsulation of a tuberculosis subunit vaccine candidate containing a nanoemulsion adjuvant via spray drying
- Author
-
Joseph McCollum, Mellissa Gomez, Ryan M. Kramer, Mani Ordoubadi, Alana Gerhardt, Zheng Wang, Michelle Archer, Christopher B. Fox, Chris Press, David Barona, Shabab Bin Karim, Reinhard Vehring, Hui Wang, and Nicholas B. Carrigy
- Subjects
Materials science ,Chemistry, Pharmaceutical ,Drug Compounding ,Drug Storage ,medicine.medical_treatment ,Protein subunit ,Pharmaceutical Science ,02 engineering and technology ,030226 pharmacology & pharmacy ,Article ,Excipients ,Liquid product ,03 medical and health sciences ,0302 clinical medicine ,Adjuvants, Immunologic ,Drug Stability ,medicine ,Humans ,Tuberculosis ,Particle Size ,Microparticle ,Tuberculosis Vaccines ,Thermostability ,Chromatography ,Spray Drying ,General Medicine ,021001 nanoscience & nanotechnology ,Nano encapsulation ,Dry powder ,Spray drying ,Vaccines, Subunit ,Nanoparticles ,Emulsions ,Powders ,0210 nano-technology ,Adjuvant ,Biotechnology - Abstract
Spray drying is a technique that can be used to stabilize biopharmaceuticals, such as vaccines, within dry particles. Compared to liquid pharmaceutical products, dry powder has the potential to reduce costs associated with refrigerated storage and transportation. In this study, spray drying was investigated for processing an adjuvanted tuberculosis subunit vaccine, formulated as an oil-in-water nanoemulsion, into a dry powder composed of microparticles. Applying in-silico approaches to the development of formulation and processing conditions, successful encapsulation of the adjuvanted vaccine within amorphous microparticles was achieved in only one iteration, with high retention (>90%) of both the antigen and adjuvant system. Moisture-controlled stability studies on the powder were conducted over 26 months at temperatures up to 40 °C. Results showed that the powder was physically stable after 26 months of storage for all tested temperatures. Adjuvant system integrity was maintained at temperatures up to 25 °C after 26 months and after one month of storage at 40 °C. The spray-dried product demonstrated improved antigen thermostability when stored above refrigerated temperatures as compared to the liquid product. These results demonstrate the feasibility of spray drying as a method of encapsulating and stabilizing an adjuvanted vaccine.
- Published
- 2021